CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF BRONCHODILATOR DRUGS IN BRONCHIAL ASTHMA

Abstract

This article examines the clinical-pharmacological principles of bronchodilator therapy in bronchial asthma, focusing on the mechanisms of drug action, patient-specific considerations, rational prescription strategies, and safety monitoring. A detailed comparative analysis of short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), anticholinergics, methylxanthines, and combination therapies is provided. Special attention is given to evidence-based approaches, international clinical guidelines, and recent pharmacological advances aimed at optimizing individualized asthma management. The article also evaluates risks, benefits, and therapeutic outcomes associated with bronchodilator use, with examples from advanced international clinical practice.